Clinical Trial

Study of the Steroid Hormone Milieu in Obese Patients

Study acronym: MiSterO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity. It will be also investigated if this hormonal milieu is a predictive factor for cardiovascular disease in obese patients. Eligible subjects are male patients (age 18-80 years) with severe obesity and no other known causes of hypercortisolism or hypogonadism. Questionnaires for the evaluation of mood and symptoms will be collected upon enrollment, patient's anamnestic and clinical data relating to disease complications, BMI, previous blood tests, cortisol suppression with dexamethasone 1 mg will be collected, and blood sample will be sent to and analyzed at a centralized laboratory for the study of Steroid hormones, bone metabolism, lipoprotein function, genetics and receptor analysis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-25.
Trial Details
NCT Number NCT06341699
Lead Sponsor Istituto Auxologico Italiano
Collaborators: Ministry of Health, Italy
Conditions Obesity, Morbid
Enrollment 180 participants
Start Date 2023-05-16
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-13